[{"id":"ec361a88-10be-462e-b8c7-8fa193d6a067","acronym":"","url":"https://clinicaltrials.gov/study/NCT03418038","created_at":"2021-01-18T16:51:47.082Z","updated_at":"2024-07-02T16:35:11.929Z","phase":"Phase 2","brief_title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT03418038","lead_sponsor":"Mayo Clinic","biomarkers":" IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation","tags":["IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-02"},{"id":"e83462de-87f7-4dab-90df-3962b5abd242","acronym":"","url":"https://clinicaltrials.gov/study/NCT01823198","created_at":"2021-01-18T08:06:03.874Z","updated_at":"2024-07-02T16:35:30.156Z","phase":"Phase 1/2","brief_title":"Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies","source_id_and_acronym":"NCT01823198","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • DNMT3A • TET2","pipe":" | ","alterations":" FLT3 mutation • KIT mutation • DNMT3A mutation • TET2 mutation","tags":["FLT3 • DNMT3A • TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • KIT mutation • DNMT3A mutation • TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • Proleukin (aldesleukin) • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 06/11/2013","start_date":" 06/11/2013","primary_txt":" Primary completion: 05/10/2022","primary_completion_date":" 05/10/2022","study_txt":" Completion: 05/10/2022","study_completion_date":" 05/10/2022","last_update_posted":"2023-11-07"},{"id":"57d644a2-7988-4d7c-b469-e62a58aafbfa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02960646","created_at":"2021-01-18T14:32:35.822Z","updated_at":"2024-07-02T16:35:55.351Z","phase":"Phase 1","brief_title":"Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies","source_id_and_acronym":"NCT02960646","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • DNMT3A • ASXL1 • KMT2A • TET2 • PHF6","pipe":" | ","alterations":" FLT3 mutation • DNMT3A mutation • Chr t(4;14) • Chr t(14;16) • MLL rearrangement","tags":["FLT3 • DNMT3A • ASXL1 • KMT2A • TET2 • PHF6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • DNMT3A mutation • Chr t(4;14) • Chr t(14;16) • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/18/2017","start_date":" 01/18/2017","primary_txt":" Primary completion: 02/13/2023","primary_completion_date":" 02/13/2023","study_txt":" Completion: 02/13/2023","study_completion_date":" 02/13/2023","last_update_posted":"2023-02-16"},{"id":"7d0269ef-d62a-464e-b888-7fb2fa28d120","acronym":"","url":"https://clinicaltrials.gov/study/NCT05250362","created_at":"2022-02-22T13:52:32.086Z","updated_at":"2024-07-02T16:36:15.354Z","phase":"Phase 1/2","brief_title":"Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT05250362","lead_sponsor":"Sichuan University","biomarkers":" FLT3 • DNMT3A • TET2","pipe":" | ","alterations":" FLT3 mutation • DNMT3A mutation • Chr del(7q)","tags":["FLT3 • DNMT3A • TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • DNMT3A mutation • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-03-15"},{"id":"544d4614-f791-4bd3-b59b-92ae1a8a0f06","acronym":"","url":"https://clinicaltrials.gov/study/NCT02497404","created_at":"2021-01-18T12:02:35.681Z","updated_at":"2024-07-02T16:36:24.176Z","phase":"Phase 2","brief_title":"Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR","source_id_and_acronym":"NCT02497404","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" FLT3 • DNMT3A • RUNX1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • ZRSR2","pipe":" | ","alterations":" DNMT3A mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • U2AF1 mutation","tags":["FLT3 • DNMT3A • RUNX1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DNMT3A mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Campath (alemtuzumab) • melphalan • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 02/13/2015","start_date":" 02/13/2015","primary_txt":" Primary completion: 06/17/2020","primary_completion_date":" 06/17/2020","study_txt":" Completion: 06/17/2021","study_completion_date":" 06/17/2021","last_update_posted":"2021-09-22"},{"id":"5468a9ed-3939-4136-ba65-8af18e922582","acronym":"","url":"https://clinicaltrials.gov/study/NCT03771222","created_at":"2021-01-18T18:39:29.431Z","updated_at":"2024-07-02T16:37:04.706Z","phase":"Phase 2","brief_title":"Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies","source_id_and_acronym":"NCT03771222","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" TP53 • FLT3 • DNMT3A • TET2","pipe":" | ","alterations":" FLT3-ITD mutation • DNMT3A mutation • TET2 mutation","tags":["TP53 • FLT3 • DNMT3A • TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • DNMT3A mutation • TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2018-12-13"},{"id":"6e2bc0cd-0b27-4b8b-b4cf-d2d75c0f287a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03365661","created_at":"2021-01-18T16:36:35.414Z","updated_at":"2024-07-02T16:37:05.437Z","phase":"Phase 2","brief_title":"QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML","source_id_and_acronym":"NCT03365661","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" TP53 • FLT3 • KIT • DNMT3A • RUNX1 • ASXL1 • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • FLT3 mutation • KIT mutation • DNMT3A mutation • ASXL1 mutation","tags":["TP53 • FLT3 • KIT • DNMT3A • RUNX1 • ASXL1 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • FLT3 mutation • KIT mutation • DNMT3A mutation • ASXL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/30/2018","start_date":" 10/30/2018","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2018-11-09"}]